Rhythm Pharmaceuticals, Inc. Common Stock (RYTM) is a publicly traded Healthcare sector company. As of July 26, 2026, RYTM trades at $102.10 with a market cap of $7.00B and a P/E ratio of -32.86. RYTM moved -0.56% today. Year to date, RYTM is -4.62%; over the trailing twelve months it is +16.99%. Its 52-week range spans $45.91 to $122.20. Analyst consensus is strong buy with an average price target of $137.09. Rallies surfaces RYTM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Setmelanotide Yields 18.9% BMI Drop in HO, 9.8% Loss in BBS, 3.06% in PWS: Setmelanotide therapy delivered a mean 18.9% BMI reduction over 2.5 years in 11 acquired hypothalamic obesity patients, while bivamelagon yielded up to a 16.6% BMI decline at one year in 26 participants. Real-world data in 286 Bardet-Biedl syndrome patients showed a 9.8% mean weight loss with 62% of adults achieving ≥10% body weight reduction, and six-month Phase 2 Prader-Willi results in 18 patients reported a 3.06% BMI drop with consistent safety.
| Metric | Value |
|---|---|
| Price | $102.10 |
| Market Cap | $7.00B |
| P/E Ratio | -32.86 |
| EPS | $-3.11 |
| Dividend Yield | 0.00% |
| 52-Week High | $122.20 |
| 52-Week Low | $45.91 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $189.76M |
| Net Income | $-196.54M |
| Gross Margin | 89.73% |
12 analysts cover RYTM: 0 strong buy, 12 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $137.09.